Related Experiment Video
Updated: Jun 11, 2025
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
PROTACs in gynecological cancers: Current knowledge and future potential as a treatment strategy
Fatemeh Movahed1, Zahra Ourang2, Razieh Neshat3
1Department of Gynecology and Obstetrics, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:
Cancer continues to threaten human health regardless of novel therapeutic options. Over the last two decades, targeted therapy has emerged as a significant advancement in treating malignancies, surpassing standard chemoradiotherapy and surgical procedures. Gynecological malignancies, including cervical, endometrial, and ovarian carcinoma, have a bad prognosis in advanced or metastatic stages and are difficult to treat. The advancements in understanding the molecular pathways behind cancer development offer valuable insights into promising targeted medicines, and researchers have always searched for a superior and safe technique to target cancer-related oncoproteins because of the limited therapeutic benefit, drug resistance, and off-target effects of current targeted treatments. Recently, proteolysis-targeting chimeras (PROTACs) have been developed to selectively degrade proteins using the natural ubiquitin-proteasome system (UPS). These approaches have garnered significant attention in the field of cancer research. The rapid progress in PROTACs has also eased the targeting of various oncoproteins in gynecological cancer. Therefore, this review aims to elucidate the mechanism and research advancements of PROTACs and provide a comprehensive overview of their use in gynecological tumors.
Insights
Proteolysis-targeting chimeras (PROTACs) offer a novel approach to degrade cancer-causing proteins. This review explores PROTAC advancements for treating difficult gynecological cancers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Targeted therapy has advanced cancer treatment, but challenges remain for gynecological malignancies.
- Current targeted treatments face limitations like drug resistance and off-target effects.
- New strategies are needed to effectively target cancer-related oncoproteins.
Purpose of the Study:
- To review the mechanism and advancements of proteolysis-targeting chimeras (PROTACs).
- To provide a comprehensive overview of PROTAC applications in gynecological tumors.
- To highlight PROTACs as a promising therapeutic strategy for gynecological cancers.
Main Methods:
- Review of recent scientific literature on PROTAC technology.
- Analysis of PROTAC mechanisms targeting the ubiquitin-proteasome system (UPS).
- Examination of PROTAC research specifically in cervical, endometrial, and ovarian cancers.
Main Results:
- PROTACs selectively degrade target proteins via the UPS.
- PROTACs show potential in overcoming limitations of current targeted therapies.
- Emerging research demonstrates PROTACs' efficacy in targeting oncoproteins in gynecological cancers.
Conclusions:
- PROTACs represent a significant advancement in targeted cancer therapy.
- PROTAC technology offers a promising avenue for treating advanced or metastatic gynecological cancers.
- Further research into PROTACs could lead to improved therapeutic outcomes for patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...